On March 31, 2026, AEON Biopharma, Inc. received a notice from NYSE for failing to meet listing standards due to a stockholders’ deficit of approximately $55 million and reported losses in three of the last four fiscal years. The company is working on a plan to regain compliance by August 3, 2026, but the notice does not affect current stock trading.